Answer
The selected intravenous product is licensed with specified chemotherapy for certain previously untreated, HER2-positive metastatic cancers of the stomach or gastro-oesophageal junction. The selected subcutaneous product is not licensed for this use.
Sources for this answer
- Herceptin 600 mg Solution for Injection in Vial — Current selected SmPCemc · Summary of Product Characteristics
- Herceptin 150mg Powder for concentrate for solution for infusion — Current selected SmPCemc · Summary of Product Characteristics